OTC review panel for botanical products should be FDA priority, commission advises.
This article was originally published in The Tan Sheet
Executive Summary
OTC REVIEW PANEL FOR BOTANICALS SUGGESTED AS FDA PRIORITY by the Commission on Dietary Supplement Labels in a draft report on supplement labeling claims and statements released June 24. "The commission strongly recommends that FDA put a priority on establishing an OTC review panel for botanical products that are intended for therapeutic and preventive use, with appropriate representation of experts on such products, at the earliest possible time," and that "FDA move forward promptly with such a review," the draft report declares. The panel should include experts with a background in pharmacognosy as well as other disciplines, the commission advises.